Pro-inflammatory mechanisms in diabetic neuropathy: focus on the Nuclear Factor Kappa B Pathway

Norman E Cameron, Mary Anne Cotter

Research output: Contribution to journalArticle

109 Citations (Scopus)

Abstract

Neuropathy is a common complication of diabetes mellitus, which reduces the quality of life and may be life-threatening. The etiology is complex and multifactorial: hyperglycemia and dyslipidemia give rise to oxidative stress and formation of advanced glycation and lipoxidation end products. These stimulate inflammatory processes, nuclear factor B (NF kappa B) activation being of central importance. Many of the drugs that have been developed for treatment of diabetic complication at least in part work through suppressing either NF kappa B activation itself, or the production of cytokines that stimulate NF kappa B, such as tumor necrosis factor (TNF) alpha. To date there have been few tests of drugs that are specific inhibitors of the NF kappa B/TNF alpha axis. However preliminary results in animal models are encouraging and go some way in establishing the NF kappa B cascade as an important therapeutic target for diabetic vascular complications in general, and neuropathy in particular.
Original languageEnglish
Pages (from-to)60-67
Number of pages8
JournalCurrent Drug Targets
Volume9
Issue number1
Publication statusPublished - Jan 2008

Keywords

  • alpha-lipoic acid
  • necrosis-factor-alpha
  • protein-kinase-C
  • aldose reductase inhibition
  • nerve-conduction velocity
  • poly(ADP-ribose) polymerase activation
  • cultured endothelial-cells
  • Impaired glucose-tolerance
  • mouse corpus cavernosum
  • good glycemic control

Cite this

Pro-inflammatory mechanisms in diabetic neuropathy : focus on the Nuclear Factor Kappa B Pathway. / Cameron, Norman E; Cotter, Mary Anne.

In: Current Drug Targets, Vol. 9, No. 1, 01.2008, p. 60-67.

Research output: Contribution to journalArticle

Cameron, Norman E ; Cotter, Mary Anne. / Pro-inflammatory mechanisms in diabetic neuropathy : focus on the Nuclear Factor Kappa B Pathway. In: Current Drug Targets. 2008 ; Vol. 9, No. 1. pp. 60-67.
@article{5e92cd278da94cc98a1aa0272be9bb60,
title = "Pro-inflammatory mechanisms in diabetic neuropathy: focus on the Nuclear Factor Kappa B Pathway",
abstract = "Neuropathy is a common complication of diabetes mellitus, which reduces the quality of life and may be life-threatening. The etiology is complex and multifactorial: hyperglycemia and dyslipidemia give rise to oxidative stress and formation of advanced glycation and lipoxidation end products. These stimulate inflammatory processes, nuclear factor B (NF kappa B) activation being of central importance. Many of the drugs that have been developed for treatment of diabetic complication at least in part work through suppressing either NF kappa B activation itself, or the production of cytokines that stimulate NF kappa B, such as tumor necrosis factor (TNF) alpha. To date there have been few tests of drugs that are specific inhibitors of the NF kappa B/TNF alpha axis. However preliminary results in animal models are encouraging and go some way in establishing the NF kappa B cascade as an important therapeutic target for diabetic vascular complications in general, and neuropathy in particular.",
keywords = "alpha-lipoic acid, necrosis-factor-alpha, protein-kinase-C, aldose reductase inhibition, nerve-conduction velocity, poly(ADP-ribose) polymerase activation, cultured endothelial-cells, Impaired glucose-tolerance, mouse corpus cavernosum, good glycemic control",
author = "Cameron, {Norman E} and Cotter, {Mary Anne}",
year = "2008",
month = "1",
language = "English",
volume = "9",
pages = "60--67",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Pro-inflammatory mechanisms in diabetic neuropathy

T2 - focus on the Nuclear Factor Kappa B Pathway

AU - Cameron, Norman E

AU - Cotter, Mary Anne

PY - 2008/1

Y1 - 2008/1

N2 - Neuropathy is a common complication of diabetes mellitus, which reduces the quality of life and may be life-threatening. The etiology is complex and multifactorial: hyperglycemia and dyslipidemia give rise to oxidative stress and formation of advanced glycation and lipoxidation end products. These stimulate inflammatory processes, nuclear factor B (NF kappa B) activation being of central importance. Many of the drugs that have been developed for treatment of diabetic complication at least in part work through suppressing either NF kappa B activation itself, or the production of cytokines that stimulate NF kappa B, such as tumor necrosis factor (TNF) alpha. To date there have been few tests of drugs that are specific inhibitors of the NF kappa B/TNF alpha axis. However preliminary results in animal models are encouraging and go some way in establishing the NF kappa B cascade as an important therapeutic target for diabetic vascular complications in general, and neuropathy in particular.

AB - Neuropathy is a common complication of diabetes mellitus, which reduces the quality of life and may be life-threatening. The etiology is complex and multifactorial: hyperglycemia and dyslipidemia give rise to oxidative stress and formation of advanced glycation and lipoxidation end products. These stimulate inflammatory processes, nuclear factor B (NF kappa B) activation being of central importance. Many of the drugs that have been developed for treatment of diabetic complication at least in part work through suppressing either NF kappa B activation itself, or the production of cytokines that stimulate NF kappa B, such as tumor necrosis factor (TNF) alpha. To date there have been few tests of drugs that are specific inhibitors of the NF kappa B/TNF alpha axis. However preliminary results in animal models are encouraging and go some way in establishing the NF kappa B cascade as an important therapeutic target for diabetic vascular complications in general, and neuropathy in particular.

KW - alpha-lipoic acid

KW - necrosis-factor-alpha

KW - protein-kinase-C

KW - aldose reductase inhibition

KW - nerve-conduction velocity

KW - poly(ADP-ribose) polymerase activation

KW - cultured endothelial-cells

KW - Impaired glucose-tolerance

KW - mouse corpus cavernosum

KW - good glycemic control

M3 - Article

VL - 9

SP - 60

EP - 67

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 1

ER -